Paid Clinical Trials Baton Rouge

Discover 247 paid clinical trials in Baton Rouge, Louisiana. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 247

Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With AsthmaEvaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma

Recruiting

PHASE3

Sponsor:

AstraZeneca

Location:

Lafayette LA, New Orleans LA, Beaumont TX, Baytown TXshow 70 more

Code:

NCT06307665

Conditions

Asthma

Eligibility Criteria

Sex: All

Age: 12 - 17

Healthy Volunteers: Not accepted

Interventions

BDA MDI

AS MDI

A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

Recruiting

PHASE3

Sponsor:

Eli Lilly and Company

Location:

Baton Rouge LA, Fayette MS, Lake Charles LA, Ridgeland MSshow 172 more

Code:

NCT05026866

Conditions

Alzheimer Disease

Eligibility Criteria

Sex: All

Age: 65 - 70+

Healthy Volunteers: Not accepted

Interventions

Donanemab

Placebo

A Study to Investigate the Effect on Lung Function of BDA Formulated With a New Propellant (HFO) Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With AsthmaA Study to Investigate the Effect on Lung Function of BDA Formulated With a New Propellant (HFO) Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With Asthma

Recruiting

PHASE3

Sponsor:

AstraZeneca

Location:

Lafayette LA, New Orleans LA, Mobile AL, Kingwood TXshow 62 more

Code:

NCT06502366

Conditions

Asthma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

BDA MDI HFO 160/180 μg

BDA MDI HFA 160/180 μg

Placebo MDI HFA

Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset EpilepsyStudy to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

Recruiting

PHASE2

PHASE3

Sponsor:

Biohaven Therapeutics Ltd.

Location:

Baton Rouge LA, New Orleans LA, Shreveport LA, Houston TXshow 27 more

Code:

NCT06309966

Conditions

Focal Epilepsy

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

BHV-7000

Placebo

Effect of Pulsatile Hormone Administration on Insulin ActionEffect of Pulsatile Hormone Administration on Insulin Action

Recruiting

Sponsor:

Pennington Biomedical Research Center

Location:

Baton Rouge LA

Code:

NCT06216665

Conditions

Insulin Sensitivity

Eligibility Criteria

Sex: All

Age: 50 - 70+

Healthy Volunteers: Not accepted

Interventions

Continuous Insulin administration during hyperinsulinemic euglycemic clamp test

Pulsatile Insulin administration during hyperinsulinemic euglycemic clamp test

Lifestyle Intervention for Improving Insulin Resistance and Concern for HealthLifestyle Intervention for Improving Insulin Resistance and Concern for Health

Recruiting

Sponsor:

Pennington Biomedical Research Center

Location:

Baton Rouge LA

Code:

NCT05649176

Conditions

Insulin Sensitivity

Apathy

Eligibility Criteria

Sex: All

Age: 50 - 70+

Healthy Volunteers: Not accepted

Interventions

Diet without soy

Diet with soy

Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal AdenocarcinomaStudy of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Recruiting

PHASE3

Sponsor:

Arcus Biosciences, Inc.

Location:

Baton Rouge LA, Hattiesburg MS, Dallas TX, Atlanta GAshow 20 more

Code:

NCT06608927

Conditions

Metastatic Pancreatic Ductal Adenocarcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Quemliclustat

Placebo

Nab-paclitaxel

Gemcitabine

Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune DiseaseTwo-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease

Recruiting

PHASE2

Sponsor:

Novartis Pharmaceuticals

Location:

Baton Rouge LA, Spring TX, Bellaire TX, Memphis TNshow 14 more

Code:

NCT06293365

Conditions

Sjögrens Disease

Systemic Lupus Erythematosus

Rheumatoid Arthritis

Eligibility Criteria

Sex: All

Age: 18 - 70

Healthy Volunteers: Not accepted

Interventions

VAY736 1ml PFS

VAY736 2 ml PFS

VAY736 2ml AI

Bupropion to Reduce Cancer Related Fatigue in Cancer SurvivorsBupropion to Reduce Cancer Related Fatigue in Cancer Survivors

Recruiting

PHASE3

Sponsor:

University of Rochester NCORP Research Base

Location:

Baton Rouge LA, Kenner LA, Covington LA, Houma LAshow 290 more

Code:

NCT03996265

Conditions

Be Diagnosed With Cancer and Have Completed Systemic Therapy

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Bupropion Hydrochloride Controlled-release

Placebo Administration

Quality-of-Life Assessment

Questionnaire Administration

Activity and Safety of Danvatirsen and Pembrolizumab in HNSCCActivity and Safety of Danvatirsen and Pembrolizumab in HNSCC

Recruiting

PHASE2

Sponsor:

Flamingo Therapeutics NV

Location:

Baton Rouge LA, Dallas TX, Atlanta GA, Greenville SCshow 16 more

Code:

NCT05814666

Conditions

HNSCC

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Danvatirsen

Pembrolizumab